JUAN OMS: Open Payments
NPI 1508067679 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,856 in 90 payments from 14 companies in 2025. Trend: 2023 $2,305 · 2024 $3,177 · 2025 $2,856
Food & beverage: $2,856
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $535 |
| E.R. Squibb & Sons, L.L.C. | 13 | $406 |
| Neurocrine BioSciences, Inc. | 5 | $312 |
| Alkermes, Inc. | 13 | $296 |
| Indivior Inc. | 9 | $296 |
| Otsuka America Pharmaceutical, Inc. | 5 | $220 |
| Janssen Pharmaceuticals, Inc | 8 | $179 |
| Luye Pharma (USA) Ltd. | 3 | $159 |
| Vanda Pharmaceuticals Inc. | 6 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $127 |
Products named: UZEDY, COBENFY, INGREZZA, SUBLOCADE, VIVITROL, REXULTI, INVEGA SUSTENNA, ERZOFRI EXTENDED-RELEASE.
Industry payments across FL — which companies pay providers there.
